Allianz Asset Management GmbH Invests $14.28 Million in Aurinia Pharmaceuticals Inc $AUPH

Key Points

• Allianz Asset Management acquired 841,731 Aurinia Pharmaceuticals shares worth approximately $14.28 million, representing a 0.63% stake. Hedge funds and institutional investors collectively own 36.83% of the company.
• Aurinia reported quarterly EPS of $0.28, beating the $0.24 consensus estimate, while revenue of $58.57 million fell short of the $80.45 million forecast.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $17.67, compared with the stock’s reported price of $16.07.

Allianz Asset Management GmbH bought a new position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP during the second quarter, according to its most recent disclosure with the SEC. The firm bought 841,731 shares of the biotechnology company's stock, valued at approximately $14,284,000. Allianz Asset Management GmbH owned 0.63% of Aurinia Pharmaceuticals as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. MML Investors Services LLC raised its stake in shares of Aurinia Pharmaceuticals by 12.7% in the fourth quarter. MML Investors Services LLC now owns 15,643 shares of the biotechnology company's stock worth $250,000 after buying an additional 1,765 shares during the period. First Trust Advisors LP boosted its position in shares of Aurinia Pharmaceuticals by 15.5% in the first quarter. First Trust Advisors LP now owns 14,065 shares of the biotechnology company's stock worth $208,000 after purchasing an additional 1,883 shares during the period. BOK Financial Private Wealth Inc. purchased a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter worth $32,000. Nykredit A S purchased a new stake in shares of Aurinia Pharmaceuticals in the second quarter worth $35,000. Finally, Global Retirement Partners LLC bought a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter valued at $41,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Price Performance

Aurinia Pharmaceuticals stock opened at $16.07 on Wednesday. Aurinia Pharmaceuticals Inc has a 12-month low of $10.34 and a 12-month high of $19.25. The company has a current ratio of 5.42, a quick ratio of 4.97 and a debt-to-equity ratio of 0.07. The firm has a 50-day moving average price of $15.78 and a 200-day moving average price of $15.58. The firm has a market capitalization of $2.14 billion, a PE ratio of 7.02 and a beta of 1.40.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.24 by $0.04. The company had revenue of $58.57 million for the quarter, compared to the consensus estimate of $80.45 million. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%. As a group, equities research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.79 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Royal Bank Of Canada lifted their target price on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a "sector perform" rating in a research note on Friday, August 7th. Weiss Ratings upgraded Aurinia Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, August 26th. Bloom Burton upgraded Aurinia Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 20th. Zacks Research cut Aurinia Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 21st. Finally, Wall Street Zen downgraded Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $17.67.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company's proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company's lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.